Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation | Zendy

Altan Onat | Zendy; Günay Can | Zendy; Gülay Hergenç | Zendy; Mehmet Yazıcı | Zendy; Ahmet Karabulut | Zendy; S. Albayrak | Zendy

Open Access

Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation

Author(s) -

Altan Onat,

Günay Can,

Gülay Hergenç,

Mehmet Yazıcı,

Ahmet Karabulut,

S. Albayrak

Publication year - 2007

Publication title -

international journal of obesity

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.663

H-Index - 225

eISSN - 1476-5497

pISSN - 0307-0565

DOI - 10.1038/sj.ijo.0803552

Subject(s) - dyslipidemia , medicine , waist , metabolic syndrome , endocrinology , apolipoprotein b , confounding , diabetes mellitus , triglyceride , c reactive protein , obesity , body mass index , high density lipoprotein , risk factor , logistic regression , cholesterol , inflammation

To investigate the role of serum apolipoprotein (apo) B levels in predicting metabolic syndrome (MS), hypertension, atherogenic dyslipidemia and type II diabetes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research